Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CDT1
REST API REST API
Homo sapiens
CDT1 is differentially expressed in 280 experiments: 95 organism parts: bone marrow, blood, ... (93 more);, 186 disease states: normal, acute lymphoblastic leukemia, ... (184 more);, 91 cell types 343 cell lines 41 compound treatments and 78 other conditions.
Synonyms DUP, RIS2
Orthologs CDT1 (Bos taurus)   Cdt1 (Rattus norvegicus)   cdt1 (Danio rerio)   Cdt1 (Mus musculus)   CDT1 (Gallus gallus)   dup (Drosophila melanogaster)   cdt1 (Xenopus laevis)   CDT1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, DNA binding, DNA replication checkpoint, protein binding, mitotic cell cycle, G1/S transition of mitotic cell cycle, nucleus, nucleoplasm, S phase of mitotic cell cycle, DNA replication, regulation of DNA-dependent DNA replication initiation, regulation of S phase of mitotic cell cycle, regulation of transcription involved in G1/S phase of mitotic cell cycle, M/G1 transition of mitotic cell cycle
InterPro Term DNA_replication_fac_CDT1-like
UniProt Accession Q9H211
Gene-Disease Assocation MEIER-GORLIN SYNDROME 4; MGORS4
Search EB-eye ENSG00000167513
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MTAB-24, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (33 experiments)

Factor Value U/D Experiments
HL-60
2
E-GEOD-5258, E-MTAB-37
A549
2
E-GEOD-3202, E-GEOD-6013
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MOLT4
2
E-MTAB-37, E-MTAB-62
MCF-7
1
2
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
SUM149PT
1
E-MTAB-62
337 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, ... (46 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
leydig cell
1
E-MTAB-25
activated natural killer cell (supplemented for IL2 for 2 hours)
1
E-TABM-702
85 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1121, E-GEOD-16363, E-MTAB-62, E-GEOD-8607, ... (49 experiments)

Factor Value U/D Experiments
extranodal NK/T-cell lymphoma
2
E-GEOD-19067, E-TABM-702
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
colon carcinoma
2
E-GEOD-3726, E-MTAB-62
glioblastoma
2
E-MTAB-37, E-GEOD-4290
lung adenocarcinoma
1
2
E-MTAB-37, E-MTAB-62, E-GEOD-2514
acute lymphoblastic leukemia
1
2
E-MTAB-62, E-MTAB-37, E-GEOD-96
180 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (26 experiments)

Factor Value U/D Experiments
none
2
6
E-GEOD-5824, E-MEXP-1601, E-TABM-782, E-GEOD-4600, E-GEOD-7400, ... (8 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
ox-LDL
1
E-GEOD-5741
placebo
1
E-MEXP-1335
CNOT7 + non-targeting
1
1
E-MEXP-2218
phoshate buffered saline
1
E-GEOD-3720
35 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
49 years
1
1
E-GEOD-4922


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-2034, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, E-GEOD-19665, ... (6 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-22593, E-GEOD-18005, E-TABM-868, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-GEOD-12773, E-GEOD-20540, E-GEOD-20504, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (27 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980, ... (7 experiments)

Injury
studied in E-GEOD-19743, E-GEOD-5372

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (7 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-GEOD-3697, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743, E-GEOD-7307, E-GEOD-21521

Stimulation
studied in E-GEOD-4883, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-22152, E-MEXP-973, E-GEOD-19246, E-GEOD-19136, ... (8 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-4922, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.351 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM